New ALS Drug Extends Survival in Groundbreaking Trial

For the first time in years, researchers have spotted something rare in ALS treatment: objective evidence that a new therapy can actually slow the disease while extending lives.

AP-101, an antibody therapy developed by AL-S Pharma, significantly prolonged survival and delayed the need for ventilation in 73 adults with ALS during a Phase 2 clinical trial. The results were presented last week at the AD/PD 2026 International Conference on Alzheimer's and Parkinson's Diseases.

ALS, also known as Lou Gehrig's disease, destroys the nerve cells that control movement and breathing. Most patients die within three to five years of diagnosis, and current treatments offer limited benefits.

The new therapy targets misfolded SOD1 proteins that form toxic clumps in some ALS patients. These clumps damage motor neurons, the specialized nerve cells essential for both voluntary movement like walking and involuntary actions like breathing.

In the trial's first six months, participants received either AP-101 or a placebo. Then everyone switched to the active treatment for another six months.

Patients who started AP-101 immediately lived longer and maintained their breathing ability better than those who waited six months to begin. Some patients even showed improved functional ability, a nearly unheard-of outcome in ALS trials.

"These data show something we rarely see in ALS: objective evidence of clinically meaningful disease modification that tracks directly with prolonged survival," said Dr. Angela Genge, chief medical officer of AL-S Pharma.

The treatment also reduced blood markers of nerve cell death, suggesting it addresses underlying disease mechanisms rather than just managing symptoms. The effects appeared in both sporadic ALS cases and those linked to inherited SOD1 mutations.

The Bright Side

While AP-101 was designed for patients with SOD1 mutations, researchers found misfolded SOD1 proteins in some ALS patients without the mutation. This discovery could mean the treatment helps a broader group than initially expected.

Top-line results announced last year already showed AP-101 was safe and well tolerated. Now, with survival data supporting its effectiveness, AL-S Pharma plans to launch a confirmatory Phase 3 trial later this year.

For the 5,000 Americans diagnosed with ALS each year, news of any treatment extending survival represents real hope. This therapy offers something even more valuable: evidence that scientists can actually modify the course of this devastating disease.

The road from Phase 3 trials to FDA approval typically takes several years, but for families facing ALS, this progress represents a meaningful step forward in a fight that has seen too few victories.